Permira Makes Substantial Growth Investment in PharmaCord

Mercalis and PharmaCord Merge and Rebrand as Valeris

May 27, 2025

Healthcare Services

Mercalis and PharmaCord have completed their previously announced merger and rebranded the combined company as Valeris. The new, PE-backed (Permira and Odyssey Investment Partners) company will offer integrated commercialization services — including data & insights, patient support services, and HCP engagement tools — to life sciences customers.

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services

July 14, 2025

Healthcare Services

PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.

Funds Advised by Permira Acquire Neuraxpharm from Funds Advised by Apax Partners

September 22, 2020

Pharmaceuticals

Funds advised by Permira have agreed to acquire the controlling stake in Neuraxpharm, a leading European specialty pharmaceuticals company focused on central nervous system (CNS) disorders, from funds advised by Apax Partners. Financial terms were not disclosed; Neuraxpharm had annual revenues in excess of €460 million and around 850 employees under Apax's ownership.

Ampersand Capital Partners Invests in Alliance Pharma

November 18, 2021

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.

Permira Acquires Majority Stake in Reorg from Warburg Pincus

August 1, 2022

Data & Analytics

Funds advised by Permira agreed to acquire the majority shareholding in Reorg from Warburg Pincus, with Reorg management retaining a significant ownership stake. The investment will support product innovation and accelerated growth for Reorg, a provider of data, analytics and intelligence for the global credit markets; financial terms were not disclosed and the deal was expected to close in Q3 2022.